Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
83.67
-3.49 (-4.00%)
At close: Apr 28, 2026, 4:00 PM EDT
84.00
+0.33 (0.39%)
After-hours: Apr 28, 2026, 4:15 PM EDT
Dianthus Therapeutics Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for Dianthus Therapeutics stock have an average target of 121, with a low estimate of 65 and a high estimate of 200. The average target predicts an increase of 44.62% from the current stock price of 83.67.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Dianthus Therapeutics stock from 13 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 5 | 6 | 7 | 7 |
| Buy | 5 | 4 | 4 | 4 | 5 | 6 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 9 | 9 | 10 | 12 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wolfe Research | Wolfe Research | Buy Initiates $98 | Buy | Initiates | $98 | +17.13% | Apr 9, 2026 |
| Wells Fargo | Wells Fargo | Buy Initiates $135 | Buy | Initiates | $135 | +61.35% | Mar 19, 2026 |
| Wedbush | Wedbush | Buy Maintains $80 → $103 | Buy | Maintains | $80 → $103 | +23.10% | Mar 12, 2026 |
| Wedbush | Wedbush | Buy Maintains $55 → $80 | Buy | Maintains | $55 → $80 | -4.39% | Mar 10, 2026 |
| Raymond James | Raymond James | Buy → Strong Buy Upgrades $63 → $123 | Buy → Strong Buy | Upgrades | $63 → $123 | +47.01% | Mar 10, 2026 |
Financial Forecast
Revenue This Year
1.30M
from 2.04M
Decreased by -36.20%
Revenue Next Year
1.68M
from 1.30M
Increased by 29.48%
EPS This Year
-4.52
from -4.20
EPS Next Year
-5.07
from -4.52
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 4.2M | 6.3M | ||||||
| Avg | 1.3M | 1.7M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 106.3% | 385.0% | ||||||
| Avg | -36.2% | 29.5% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.97 | -2.92 | ||||||
| Avg | -4.52 | -5.07 | ||||||
| Low | -6.42 | -7.60 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.